1. Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure
- Author
-
Cristina Díez, María del Mar Santos, Luis Prieto, David Aguilera-Alonso, Marisa Navarro, María José Mellado, Santiago Jiménez de Ory, África Holguín, Talía Sainz, Jose Ignacio Bernardino, Sara Guillén, Miguel Gutiérrez-López, Carolina Beltrán-Pavez, and José Tomás Ramos
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adolescent ,Anti-HIV Agents ,030106 microbiology ,HIV Infections ,Viremia ,Emtricitabine ,Peripheral blood mononuclear cell ,03 medical and health sciences ,0302 clinical medicine ,Proviruses ,Drug Resistance, Viral ,Prevalence ,medicine ,AcademicSubjects/MED00740 ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Young adult ,Child ,Original Research ,Pharmacology ,business.industry ,virus diseases ,Lamivudine ,DNA ,Viral Load ,medicine.disease ,Resistance mutation ,Virology ,AcademicSubjects/MED00290 ,Infectious Diseases ,Cohort ,AcademicSubjects/MED00230 ,business ,Viral load ,medicine.drug - Abstract
Objectives We analysed the prevalence of M184V/I and/or K65R/E/N mutations archived in proviral DNA (pDNA) in youths with perinatal HIV, virological control and who previously carried these resistance mutations in historic plasma samples. Methods We included vertically HIV-infected youths/young adults aged ≥10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA Results Among the 225 patients under follow-up in the study cohort, 13 (5.8%) met selection criteria, and RT sequences were recovered in 12 (92.3%) of them. All but one were Spaniards, carrying subtype B, with a median age at PBMCs sampling of 21.3 years (IQR: 15.6–23.1) with 4 years (IQR 2.1–6.5) of suppressed viral load (VL). Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression. In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART. Conclusions The prevalence of resistance mutations to lamivudine and emtricitabine in pDNA in a cohort of youths perinatally infected with HIV who remain with undetectable VL, previously lamivudine and/or emtricitabine experienced, was infrequent. Our results indicate that ART including lamivudine or emtricitabine may also be safe and successful in youths with perinatal HIV with previous experience of and resistances to these drugs detected in plasma.
- Published
- 2021